SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : ProxyMed (PILL)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Gerry Pince who wrote ()5/2/2000 11:45:00 AM
From: tuck  Read Replies (1) of 261
 
Gerry, et. al.,

I was afraid of this. PILL's price is now so low preferred holders want to renegotiate the conversion terms.

siliconinvestor.com

Also contributing to the malaise: Mr. Blue sold most of his holdings. Because he had to:

quote.bloomberg.com.

ProxyMed Chairman Loses Most of Stake to Margin Call (Update1)
By Miles Weiss

Washington, May 1 (Bloomberg) -- ProxyMed Inc. Chairman
Harold Blue reported that most of his company stake, pledged as loan collateral, was sold by his brokerage after the shares plummeted in value.

The executive filed a Form 4 with the Securities and Exchange Commission saying 618,582 of his shares were sold pursuant to margin calls. Blue held 644,132 shares as of May 17, 1999, according to a company proxy statement.

A brokerage that loans money to a client for share purchases
requires the borrower to pledge stock as collateral. When the value of this collateral falls below a certain level, the brokerage issues a margin call, requiring the borrower to either pay down the loan immediately or have the collateral sold.

Blue, who founded ProxyMed, said in an interview he had
borrowed money to purchase about $1 million worth of company stock at prices ranging from $9 to $14 a share. ProxyMed shares fell 3/8 today to 1 1/4. ``With the precipitous decline in our share price I had a margin call and my brokerage firm sold my shares,'' Blue said.
According to the SEC filing, Blue's shares were sold between April 17 and April 27 at $1.61 to $3.50 each.

ProxyMed, a Ft. Lauderdale, Florida, online health-care
company, has seen its shares decline more than 87 percent so far this year. The stock traded as high as 16 13/16 about one year ago.

The company provides business-to-business health-care
electronic commerce services to health-care information systems providers. In addition, ProxyMed lets physicians exchange clinical and financial messages with payers, labs, pharmacies, suppliers and their patients through desktop software.

Blue declined comment on the reason that ProxyMed shares have declined. At the same time, he said the company is doing very well.
``My situation is not indicative of the company's status
right now,'' Blue said.

Let's hope. If the company isn't going out of business, this might be the bottom. But it's usually best to wait the renegotiation, and see if some news comes along to set up a conversion rally.

Good Luck All, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext